Cargando…

Re-enforcing the strategy of targeting MEK/ERK signaling to overcome acquired resistance to third generation EGFR inhibitors

Detalles Bibliográficos
Autores principales:	Zhao, Wen, Sun, Shi-Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2021
Materias:	Research Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336935/ https://www.ncbi.nlm.nih.gov/pubmed/34368397 http://dx.doi.org/10.18632/oncoscience.539

Ejemplares similares

Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
por: Yu, Danlei, et al.
Publicado: (2021)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

Emerging strategies to overcome resistance to third-generation EGFR inhibitors
por: Shi, Kunyu, et al.
Publicado: (2022)

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
por: Liu, Xuejiao, et al.
Publicado: (2019)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
por: Zang, Hongjing, et al.
Publicado: (2020)

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
por: Du, Xiaojing, et al.
Publicado: (2021)

Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance
por: Mahfoudhi, Emna, et al.
Publicado: (2022)

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
por: Zhang, Tao, et al.
Publicado: (2020)

In Vitro and In Vivo Efficacies of the EGFR/MEK/ERK Signaling Inhibitors in the Treatment of Alveolar Echinococcosis
por: Cheng, Zhe, et al.
Publicado: (2020)

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
por: Mancini, Maicol, et al.
Publicado: (2017)

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2022)

CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)
por: Qin, Qiong, et al.
Publicado: (2020)

Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
por: Zhang, Tao, et al.
Publicado: (2021)

Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
por: Zhang, Tao, et al.
Publicado: (2023)

Taking early preventive interventions to manage the challenging issue of acquired resistance to third-generation EGFR inhibitors
por: Sun, Shi-Yong
Publicado: (2023)

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
por: Ninomiya, Kiichiro, et al.
Publicado: (2018)

Taking action early to manage emergence of acquired resistance to osimertinib or other third generation EGFR inhibitors
por: Ma, Guangzhi, et al.
Publicado: (2021)

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
por: Watanabe, Sho, et al.
Publicado: (2021)

DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
por: Izquierdo, Elisa, et al.
Publicado: (2022)

Overcoming Resistance to AC0010, a Third Generation of EGFR Inhibitor, by Targeting c-MET and BCL-2
por: Xu, Wanhong, et al.
Publicado: (2018)

Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway
por: Li, Ling, et al.
Publicado: (2020)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR‐TKIs in non‐small cell lung cancer
por: Sato, Hiroki, et al.
Publicado: (2018)

Roadmap and strategy for overcoming infusion reactions to nanomedicines
por: Szebeni, Janos, et al.
Publicado: (2018)

Overcoming Regulatory Aversion to Novel Methods of Evidence Generation
por: Baumfeld Andre, Elodie, et al.
Publicado: (2019)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
por: La Monica, Silvia, et al.
Publicado: (2017)

Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling
por: Tripathi, Rakshamani, et al.
Publicado: (2020)

MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments
por: Miranda, Mariska, et al.
Publicado: (2015)

MEK Inhibitor U0126 Reverses Protection of Axons from Wallerian Degeneration Independently of MEK–ERK Signaling
por: Evans, Catherine, et al.
Publicado: (2013)

Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
por: Merchant, Mark, et al.
Publicado: (2017)

Midazolam impedes lung carcinoma cell proliferation and migration via EGFR/MEK/ERK signaling pathway
por: Zhang, Xiangchao, et al.
Publicado: (2023)

MEK inhibitors in non-V600 BRAF mutations and fusions
por: Johnson, Douglas B., et al.
Publicado: (2020)

Emergence of specialized third-party enforcement
por: Mohlin, Erik, et al.
Publicado: (2023)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
por: Tang, Kejing, et al.
Publicado: (2018)

Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells
por: Iezzi, Alice, et al.
Publicado: (2018)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2022)

Dichotomous roles of leptin and adiponectin as enforcers against lipotoxicity during feast and famine
por: Unger, Roger H., et al.
Publicado: (2013)

Preventing brain aging by the artificial enforcement of the unfolded protein response: future directions
por: Cabral-Miranda, Felipe, et al.
Publicado: (2023)

Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
por: Merchant, Mark, et al.
Publicado: (2018)

RNF128 Promotes Malignant Behaviors via EGFR/MEK/ERK Pathway in Hepatocellular Carcinoma
por: Bai, Xue-Song, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cod3a17sqjrk0nm2gbgh5o7k0h